SERVIZO GALEGO DE SAÚDE

FUNDACIÓN GALEGA DE INVESTIGACIÓN BIOMÉDICA GALICIA SUR

DIGITAL PLATFORM FOR THE PROMOTION OF VACCINATION IN IMID PATIENTS - IMIDVac

PROTECTION

Web Domain

Owners: Servicio Público de Saúde (SERGAS) and Galician Public Foundation for Biomedical Research Galicia Sur (FPGIBGS)

Inventors: Jose María Pego Reigosa, Víctor del Campo, Irene Altabás and Nuno da Costa Pereira.

BACKGROUND

Chronic Immune-Mediated Inflammatory Diseases (**IMID**), such as rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, myopathies, lupus, or Sjögren's syndrome, are characterized by an altered immune system that leads to persistent inflammation and a higher risk of infections. Patients with these conditions often receive immunosuppressive treatments, which further increase their vulnerability to preventable infections.

Although vaccination is essential to reduce these complications, vaccination rates in this group remain insufficient, partly due to the lack of clear, accessible, and tailored information. This situation creates uncertainty among both patients and healthcare professionals regarding which vaccines should be administered, when to do so, and how to coordinate them with ongoing treatments.

In response to this issue, the need was identified to develop a digital educational tool specifically aimed at IMID patients. The challenge for researchers in this field has focused on creating digital tools that centralize and simplify access to essential, personalized information about vaccination, treatments, and diseases, helping these patients proactively manage their vaccination schedule.

ACHIEVEMENTS AND RESULTS

IMIDVac is a mobile-friendly web platform that offers patients practical and straightforward information about their chronic inflammatory diseases, immunosuppressive treatments, the most common infections, and the recommended vaccines, as well as tracking of these vaccinations. The IMIDVac platform allows users to create personalized profiles, record personal data and vaccination history, and activate reminders for vaccination dates. Additionally, it provides information on common, latent, and opportunistic infections.

The development of IMIDVac involved active collaboration with patient associations (ASEARPO, AVIDEPO, AGAL), which helped improve its design and usability. The application has been very well received, as evidenced by more than 2,000 followers on social media.

PURPOSES AND ADVANTAGES

The **main advantages** of this technology are:

- Centralized and personalized access to information about diseases, treatments, and vaccination for the patient group.
- Facilitates self-management of the vaccination schedule through automatic reminders, improving adherence and reducing missed doses.
- Provides practical and accessible information tailored to the patient's real needs (doses, vaccines, pathology, common infections…), enhancing self-management and helping to understand associated risks.
- Free and multiplatform access, available via web and mobile devices.

COLLABORATION OFFER

Searching for partners for the commercialization of the product among pharmaceutical companies interested in using IMIDVac to promote vaccination among patients currently using their drugs. If you are interested or need more information about the IMIDVac App, please contact us.

WEB LINK

CONTACT INFORMATION

Nerea Alonso Sousa
Innovation and Technology Transfer Unit
Galician Public Foundation for Biomedical Research Galicia Sur- IIS Galicia Sur

Tel: +34 986 217 454
email: nerea.alonso@iisgaliciasur.es
Webs: http://www.fundacionbiomedica.org/
http://www.iisgaliciasur.es/

Proyecto financiado por:

- Independent Grant de Pfizer dentro del programa Pfizer Independent Grants for Learning & Change (IGLC)
- Pfizer Global Medical Grants.

INSTITUTO DE
INVESTIGACIÓN SANITARIA
Galicia Sur

Hospital Álvaro Cunqueiro
Estrada Clara Campoamor, 341
36312 Vigo, Pontevedra - SPAIN

www.fundacionbiomedica.org www.iisgaliciasur.es